New proprietary technology enables federated multi-nodal queries, safe harbor encoding, and cross-node query without requiring data transfer to promote enhanced data possession and security footing for data holders.
PALO ALTO, Calif.–(BUSINESS WIRE)–Atropos Health, a pioneer in automating the generation of high quality real-world evidence (RWE) today announces the launch of Nodal Patient Deidentification and Query Time Interval Encoding (Nodal Deid) across the GENEVA OS platform for members of the Atropos Evidence Network. This announcement enables Atropos Evidence Network members to fill data gaps in patients’ longitudinal records from participating Atropos Evidence Network sources to leverage robust deidentified patient records mapped to the HIPAA safe harbor standard while allowing members to maintain control over and safeguard their data . This linkage occurs only at query time to remove the need to transfer or lose possession of underlying source data.
With healthcare data more plentiful and diverse than ever, much of this data still remains siloed. In order to combine patient level data today, such as lab results and pharmacy claims, tokenization and expert determination require datasets to be copied and combined in a new location, often with source data holders losing possession of the original source data and requiring significant time and resources to complete the combination and expert determination. With Nodal Deid, sources leveraging a token of their choice can query their data through ChatRWD®, and the query will create a HIPAA safe harbor-mapped interval encoding across participating Atropos Evidence Network members at query time to create the aggregate analysis of the query across all linked attributes of relevant patient records. From question to publication grade answer in minutes across all of the relevant data elements for the study, no patient-level data is transferred to querying parties, allowing source systems to maintain data possession and minimizing the risk of disclosing identifiers.
The benefit of this approach is that aggregate studies, run in minutes on ChatRWD, will provide a more comprehensive patient longitudinal view as measured by Real World Fitness Score® (RWFS), helping to enhance data quality for every query and transparently displaying the quantitative benefit of Nodal Deid to every query. With today’s announcement, Atropos Health will make available death linkages to Atropos Evidence Network members through the GENEVA OS platform at query time, allowing every query to have accurate mortality data appended to every study through Atropos Evidence Network member Veritas Data Research.
This innovation has multiple benefits to stakeholders:
For Health Systems
By installing GENEVA OS, available from the AWS and GCP Marketplace, health systems can access linkage to other Atropos Evidence Network member data sources to fill gaps in their own data repositories, improving the utility and longitudinality of patient records. They can also form private networks, and in all cases, members have control of who can query their data and for what use case. Further, they control who is able to link their data for use. However when they do elect participation, no data is transferred to any third party, all data remains subject to the security safeguards of GENEVA OS at the time of query, and they can participate in transparent passive monetization to drive investment at their own institution and data infrastructure.
For Data Platforms
Already active participation in the Atropos Evidence Network generates demand for participating data platforms, as well as highlighting data quality and value to customers. With this announcement, data platforms can leverage the Atropos Evidence Network for data sourcing to extend and expand their existing data products for their customers and users without requiring complex transactional burdens and offering an alternative to existing data infrastructure expenses. This will allow data platforms to further increase the usability and quality of their data while reducing data cost and data enrichment burdens.
For Life Sciences Companies
This announcement represents one step closer to the flexibility and transparency pharmaceutical company users want. By querying the Atropos Evidence Network, users can now expect to get query access to the right linked data for analysis every time. This includes the ability to query between internal datasets they already use and linked Atropos Evidence Network sources. Instead of buying siloed data sets with unknown utility, users can see data quality and fitness scoring, and Nodal Deid linkage to help them leverage the right data. All of this is backed by the unmatched speed and user experience of applications like ChatRWD which enables multi-node queries in minutes without further analysis required. Backed by a decade of publications and already leveraged by top pharmaceutical companies such as Merck and Johnson & Johnson, Atropos Health drives quality and transparency for every query to support research and clinical decisions.
About Atropos Health
Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence.
To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.
Contacts
